Amendment No. 1 to License Agreement between PRAECIS Pharmaceuticals Incorporated and Pharmaceutical Applications Associates LLC

Summary

This amendment updates a previous license agreement between PRAECIS Pharmaceuticals Incorporated and Pharmaceutical Applications Associates LLC, along with individual parties C. Donald Williams and Robert Murdock. The amendment changes Section 4.6, specifying that if PRAECIS chooses to start a Phase III study of the licensed product, it must pay a specified sum to PAA within 60 days of treating the first patient. All other terms remain as defined in the original agreement.

EX-10.9 6 a2029162zex-10_9.txt EXHIBIT 10.9 EXHIBIT 10.9 CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN PORTIONS OF THIS DOCUMENT. SUCH PORTIONS HAVE BEEN REDACTED AND MARKED WITH ASTERISKS (**). THE NON-REDACTED VERSION OF THIS DOCUMENT HAS BEEN SENT TO THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT. AMENDMENT NO. 1 TO LICENSE AGREEMENT Pursuant to Section 15.2 of the License Agreement dated as of April 15, 1999 between Pharmaceutical Applications Associates LLC, C. Donald Williams, M.D., C.G.P., Robert Murdock, R.Ph. and PRAECIS PHARMACEUTICALS INCORPORATED (the "Agreement"), the parties hereto, intending to be legally bound, hereby agree as follows: Section 4.6 of the Agreement is hereby amended in its entirety to read as follows: 4.6 In the event that Licensee elects, in its sole discretion, to initiate a Phase III study of the Licensed Product, Licensee shall pay to PAA the sum of *** dollars ($***) within sixty (60) days of the treatment of the first patient. Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to such terms in the Agreement. [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] IN WITNESS WHEREOF, the parties have duly executed this Amendment No. 1 to the Agreement as of this 25th day of August, 2000. PRAECIS PHARMACEUTICALS INCORPORATED /s/ Marc A. Silver ------------------------------------------ Marc A. Silver Vice President of Corporate Development PHARMACEUTICAL APPLICATIONS ASSOCIATES LLC By /s/ C. Donald Williams, M.D., C.G.P. ------------------------------------------ Name: C. Donald Williams, M.D., C.G.P. Title: President